Compare Aterian Inc (ATER) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aterian Inc vs Cigna Corp — how do they compare? Aterian Inc trades at $1.28 (market cap $12.98M), while Cigna Corp trades at $297.59 (market cap $80.25B). The key difference: Cigna Corp is far larger — about 6182.6× Aterian Inc's market cap, and Cigna Corp pays a 2.06% dividend while Aterian Inc pays none. Which is the better fit depends on your goals.
| ATER | CI | |
|---|---|---|
Market Cap | $12.98M | $80.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $1.39 | $311.00 |
52-Week Low | $0.54 | $244.41 |
Enterprise Value | $13.56M | $103.35B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aterian (ATER) trades at $1.19, up 3.48% with a bullish technical signal despite negative profitability. Recent earnings beats and a pending asset sale that could return $0.85-$1.14 per share provide near-term catalysts. However, the company shows declining revenue from $221M in 2022 to $69M in 2025, with negative net income margins and cash flow challenges.
The outlook hinges on shareholder approval of the brand portfolio sale, offering potential shareholder returns near current price levels. Investment opportunity exists in the asset sale catalyst, but risks include ongoing operational losses, declining revenue, and negative cash flow. Analyst sentiment is evenly split between Buy and Hold recommendations.
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aterian Inc
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products, and consumer electronics. It has various owned and operated brands include Vremi, Healing Solutions, Xtava, TRUWEO, Spiralize, Pohl+Schmitt, and RIF6. The company generates revenue through the online sales of various consumer products that are sold online.
Read more on ATER →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
